<DOC>
	<DOCNO>NCT02051166</DOCNO>
	<brief_summary>The purpose study observe clinical practice include glucocorticoid treatment AECOPD China .</brief_summary>
	<brief_title>Clinical Practice AECOPD Management China</brief_title>
	<detailed_description>It widely recognize global social economic burden Chronic obstructive pulmonary disease ( COPD ) high ; affect estimate 64 million people worldwide . It report prevalence COPD China population 40 year old 8.2 % ( Zhong Nanshan et al , 2007 ) . According report China Chronic Disease , COPD second disease Disability Adjusted Life Years . The economic burden COPD tremendous China . Cost analysis 2006 show every COPD patient urban would pay 1732.24 $ medical cost every year , indirect cost nurse traffic 231.6 $ , total cost would account 40 % average family income 2006 ( Chiang CH.,2008 ) .AECOPD one important cause lead COPD death . Corticosteroid essential AECOPD management recommend domestic international guideline . But show corticosteroid use treat AECOPD China around 70 % market research big hospital , less report steroid use AECOPD management publish , include distribution , dosage , treatment duration , etc . The healthcare resource utilization treat AECOPD China also unclear .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>1 . â‰¥40 year old 2 . Hospitalization treatment due AECOPD since Sep , 2013 3 . Diagnosed GOLD 2013 COPD least 3 month AECOPD base treat physician 's judgment 4 . Provided informed consent inform consent waiver 1 . Participation interventional clinical study within 3 month recruit study . 2 . Ongoing AECOPD recruitment timeline 3 . The patient whose symptom n't recover discharge 4 . The primary diagnosis hospitalization AECOPD</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>